APOE and atherosclerosis: Perhexiline regulates the KLF14 pathway, and the results revealed that this intervention diminishes the development of atherosclerotic lesions in the apolipoprotein E-deficient mice which have a high cholesterol level and more chances for the development of atherosclerosis.